Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F McDermott

Showing results (1-10 of 227) with videos related to

Pageof 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Update on the application of interleukin-2 in the treatment of renal cell carcinomaDavid F McDermott
Medical Oncology (Northwood, London, England)|January 17, 2009
The application of high-dose interleukin-2 for metastatic renal cell carcinomaDavid F McDermott
Cancer|April 30, 2009
Immunotherapy of metastatic renal cell carcinomaDavid F McDermott
Current Clinical Pharmacology|August 11, 2011
Immunotherapy and targeted therapy combinations in renal cancerDavid F McDermott
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeuticsAlexandra Bailey, David F McDermott
Cancer Journal (Sudbury, Mass.)|August 18, 2018
Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell CarcinomaXin Gao, David F McDermott
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedsideMatthew Weinstock, David F McDermott
Expert Opinion on Investigational Drugs|December 16, 2014
Nivolumab for the treatment of cancerAnasuya Gunturi, David F McDermott
Current Treatment Options in Oncology|February 8, 2014
Potential of new therapies like anti-PD1 in kidney cancerAnasuya Gunturi, David F McDermott
Current Oncology Reports|March 23, 2013
Novel immunotherapies in GU malignanciesAlexandra Drakaki, David F McDermott
Pageof 23

Showing results (1-10 of 227) with videos related to

Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Update on the application of interleukin-2 in the treatment of renal cell carcinomaDavid F McDermott
Medical Oncology (Northwood, London, England)|January 17, 2009
The application of high-dose interleukin-2 for metastatic renal cell carcinomaDavid F McDermott
Cancer|April 30, 2009
Immunotherapy of metastatic renal cell carcinomaDavid F McDermott
Current Clinical Pharmacology|August 11, 2011
Immunotherapy and targeted therapy combinations in renal cancerDavid F McDermott
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeuticsAlexandra Bailey, David F McDermott
Cancer Journal (Sudbury, Mass.)|August 18, 2018
Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell CarcinomaXin Gao, David F McDermott
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedsideMatthew Weinstock, David F McDermott
Expert Opinion on Investigational Drugs|December 16, 2014
Nivolumab for the treatment of cancerAnasuya Gunturi, David F McDermott
Current Treatment Options in Oncology|February 8, 2014
Potential of new therapies like anti-PD1 in kidney cancerAnasuya Gunturi, David F McDermott
Current Oncology Reports|March 23, 2013
Novel immunotherapies in GU malignanciesAlexandra Drakaki, David F McDermott
Pageof 23